Online first
Review paper
Published online: 2025-01-29
New targeted therapies used in the treatment of patients with advanced cholangiocarcinoma
1
, 1, 23
, 1, 23
Abstract
Cholangiocarcinoma (CC) is a rare yet exceptionally aggressive malignancy originating from the epithelium of the bile ducts. At the time of diagnosis, most patients are already in an advanced stage of the disease and qualify only for palliative treatment. Despite advances in oncological treatment, the prognosis for patients with advanced CC remains poor. Recently, several new molecularly targeted drugs have been developed, and their use may improve the prognosis for these patients. This article presents information about new molecules used in the treatment of patients with advanced CC: pemigatinib, futibatinib, and ivosidenib.
Keywords: cholangiocarcinomamolecularly targeted therapy
References
- Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29(2): 221–232.
- Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273–1281.
- Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5): 318–332.
- Farshidfar F, Zheng S, Gingras MC, et al. Cancer Genome Atlas Network, Cancer Genome Atlas Network. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017; 18(11): 2780–2794.
- Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19(3): 235–242.
- Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014; 45(8): 1630–1638.
- Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5): 671–684.
- Goyal L, Saha SK, Liu LY, et al. Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017; 7(3): 252–263.
- Patel TH, Marcus L, Horiba MN, et al. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clin Cancer Res. 2023; 29(5): 838–842.
- Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2 Study Investigators. Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023; 388(3): 228–239.
- Zhu A, Macarulla T, Javle M, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021; 39(3_suppl): 266–266.